Onkológia S5/2024
Enzalutamide in the treatment of metastatic castration-resistant prostate cancer
Purpose: Prostate cancer is one of the most common malignant diseases by men. We can see new molecules in the treatment of this disease, that allow to prolong overall survival. In this casuistic we want to show using of enzalutamide in the treatment of metastatic hormonal sensitive prostate cancer Case: We want to demonstrate the case of patient with metastatic hormonal sensitvie prostate carcinoma treated with enzalutamide. This patient had disease diagnosed in metatastatic stadium initially. PSA before therapy with degarelix and enzalutamide was 33,76 ug/l. After one month of therapy PSA was 0,55 ug/l, after three months < 0,05 μg/l, and this value persists one year actually. The quality of life is better. The therapy is well tolerated, without tocicity, without interruption or dose reduction. According to CT there is no radiographic progression. Conclusion: This case confirmes significant therapeutic efficacy of enzalutamide.
Keywords: metastatic hormonal sensitive prostate cancer, docetaxel, enzalutamide
